Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
cervical%20cancer%20-%20treatment
CERVICAL CANCER - TREATMENT
Patients w/ abnormal Pap smear are referred for colonoscopy to screen for presence of cervical cancer.
Colposcopic exam should include inspection of the transformation zone, definition of the extent of the lesion & biopsy of the most abnormal area for tissue diagnosis.
The earliest stages of cervical carcinoma are generally asymptomatic.
Watery vaginal discharge & postcoital bleeding or intermittent spotting may be present & are usually unrecognized by the patient.

Drug Information

Indication: Unresectable or metastatic melanoma. Advanced non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1...

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Primary treatment of ovarian cancer in combination w/ platinum agent. Metastatic ovarian or breast cancer, aft...

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patients w/o prio...

Indication: Advanced stage ovarian cancer of epithelial origin.

Indication: Advanced ovarian carcinoma of epithelial origin.

Indication: Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carci...

Indication: Squamous cell carcinoma of skin, head, neck & oesophagus, larynx, penis & uterine cervix, bronchus. Ch...

1  /  4
1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Olaparib improves response, PFS over chemo in relapsed, BRCA mutated, platinum-sensitive ovarian cancer
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving ≥2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.
Netupitant‐palonosetron combo prevents chemo-induced nausea, vomiting
Audrey Abella, 09 Jul 2019
A fixed single‐dose of netupitant 300 mg plus palonosetron 0.50 mg (NEPA) was better than palonosetron and aprepitant in preventing acute and delayed* chemotherapy-induced nausea and vomiting (CINV) following multiple chemotherapy cycles, according to the results of two phase III trials.